Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

May’s top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken

Thermo Fisher Scientific agreed to acquire Dutch contract development and manufacturing organisation (CDMO) Patheon for $7.2bn. AstraZeneca entered an agreement to provide the commercial rights for Seloken / Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe to Recordati. wraps up the key headlines from May.

Go Top